Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.

To investigate the contribution of leukotrienes (LTs) to inflammation and bronchoconstriction in nocturnal asthma, we performed a randomized trial in 12 asthmatic patients and 6 normal control subjects. This study involved pulmonary function testing, methacholine challenge, bronchoscopy for cell counts, LT and thromboxane (TX) levels in bronchoalveolar lavage (BAL) fluid, and collection of urine for LTs at 4:00 P.M. and 4:00 A.M. At 4:00 P.M. BAL fluid LTB4 and sulfidopeptide LT levels in asthmatic and control subjects were not statistically different. At 4:00 A.M. alone, LTB4 and cysteinyl LT levels increased to become significantly greater in asthmatic than in control subjects, LTB4 levels correlating significantly (r = -0.66, p < 0.0001) with nocturnal fall in FEV1. Nocturnal asthmatic urinary LTE4 levels were also significantly higher than those of control subjects. The 4:00 A.M. testing was repeated during treatment with a 5-lipoxygenase inhibitor, zileuton. In asthmatic subjects, zileuton decreased BAL fluid LTB4 (p = 0.01) and urinary LTE4 (p = 0.01) while showing a trend for improving nocturnal FEV1 (p = 0.086). These decreases in LTB4 levels and improvement in FVE1 were associated with significant reductions in 4 A.M. BAL fluid and blood eosinophil percentages on zileuton compared with placebo administration. These findings demonstrate the importance of LTs in both the inflammation and the physiology of nocturnal asthma.

[1]  C. Rizzi.  Statistical Methods , 2020, Springer Theses.

[2]  L. Dubé,et al.  Pharmacokinetics and Pharmacodynamics of Zileuton after Oral Administration of Single and Multiple Dose Regimens of Zileuton 600mg in Healthy Volunteers , 1995, Clinical pharmacokinetics.

[3]  G. Granneman,et al.  Determination of a New 5-Lipoxygenase Inhibitor, Zileuton, and its Inactive N-Dehydroxylated Metabolite in Plasma by High Performance Liquid Chromatography , 1995, Clinical pharmacokinetics.

[4]  W. Busse,et al.  The Effect of Inhibition of 5-Lipoxygenase by Zileuton in Mild-to-Moderate Asthma , 1993, Annals of Internal Medicine.

[5]  T. Haahtela,et al.  Leukotriene E4 and granulocytic infiltration into asthmatic airways , 1993, The Lancet.

[6]  W. R. Beam,et al.  Timing of prednisone and alterations of airways inflammation in nocturnal asthma. , 1992, The American review of respiratory disease.

[7]  D. Postma,et al.  Blood eosinophil numbers and activity during 24 hours: effects of treatment with budesonide and bambuterol. , 1992, The Journal of allergy and clinical immunology.

[8]  P. Howarth,et al.  Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. , 1992, The American review of respiratory disease.

[9]  Joel Morris,et al.  Contribution of Leukotriene B4 to Airway Inflammation and the Effect of Antagonists , 1991, Annals of the New York Academy of Sciences.

[10]  C. Dollery,et al.  Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects , 1991, The Lancet.

[11]  R. Ballard,et al.  Airways inflammation in nocturnal asthma. , 1991, The American review of respiratory disease.

[12]  K. Resch,et al.  Eicosanoid synthesis in murine macrophages can be shifted from prostaglandins to leukotrienes but not vice versa by specific inhibitors of cyclooxygenase or 5'-lipoxygenase activity. , 1991, Advances in prostaglandin, thromboxane, and leukotriene research.

[13]  P. O'Byrne,et al.  Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. , 1990, The New England journal of medicine.

[14]  R. Martin,et al.  Circadian basis of the late asthmatic response. , 1990, The American review of respiratory disease.

[15]  Robert A. Lewis,et al.  Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.

[16]  S. Wenzel,et al.  Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. , 1990, The American review of respiratory disease.

[17]  S. Wenzel,et al.  Measurement of peptidoleukotrienes in biological fluids. , 1990, Journal of applied physiology.

[18]  R. Ballard,et al.  Factors related to the nocturnal worsening of asthma. , 1990, The American review of respiratory disease.

[19]  S. Durham,et al.  Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions. , 1989, The American review of respiratory disease.

[20]  S. Wenzel,et al.  Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. , 1989, The American review of respiratory disease.

[21]  M. Turner-Warwick,et al.  Epidemiology of nocturnal asthma. , 1988, The American journal of medicine.

[22]  W. Henderson,et al.  Eicosanoids and lung inflammation. , 1987, The American review of respiratory disease.

[23]  S. Hurd,et al.  Summary and recommendations of a workshop on the investigative use of fiberoptic bronchoscopy and bronchoalveolar lavage in asthmatic patients. , 1985, Chest.

[24]  J. Maclouf,et al.  Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. , 1985, Analytical chemistry.

[25]  A. B. Kay,et al.  Bronchoalveolar lavage in asthma: the effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins, and complement. , 1984, The Journal of allergy and clinical immunology.

[26]  S. Spector,et al.  Standardization of bronchial inhalation challenge procedures. , 1975, The Journal of allergy and clinical immunology.

[27]  G. M. Cochrane,et al.  A survey of asthma mortality in patients between ages 35 and 64 in the Greater London hospitals in 1971. , 1975, Thorax.